Mediwatch raises £347K to advance global growth strategies
This article was originally published in Clinica
Executive Summary
UK urology diagnostics specialist Mediwatch has raised £347,440 ($582, 600) through the placement of over six million new shares on the London Stock Exchange's alternative investment market, where the firm is listed. The proceeds will be used for working capital and to help realise four opportunities that the company has identified to support its international growth. These opportunities include creating a joint venture with an international partner, sharing technology and pursuing a common marketing campaign; assessing the use of Mediwatch's bioassays with another international partner; promoting its prostate-specific antigen (PSA) system for assessing urological problems alongside a partner's proprietary point-of-care system; and in-licensing and researching the use of a bladder cancer marker with the Mediwatch BioScan reader.